All In Biotech

Drug Trial Radar · NCT05261399

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).

Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 341 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

341

Actual

Start

Aug 3, 2022

Primary completion

Jul 6, 2026

Study completion Nov 23, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.

Conditions

  • Carcinoma
  • Non-Small-Cell Lung

Interventions

  • SavolitinibDrug

    300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral

  • OsimertinibDrug

    80 mg osimertinib (1 × 80 mg tablet once daily) Administrative route : oral

  • PemetrexedDrug

    Pemetrexed (500 mg/m2) Administrative route : IV infusion

  • CisplatinDrug

    Cisplatin (75 mg/m2) Administrative route : IV infusion

  • CarboplatinDrug

    Carboplatin (AUC5) Administrative route : IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib.Time frame: Approximately 36.5 months post first subject randomized

Locations

214 sites in 27 countries. Site status is shown where the registry gives one.

  • Research Site

    Orlando, Florida

  • Research Site

    Honolulu, Hawaii

  • Research Site

    New Brunswick, New Jersey

  • Research Site

    New York, New York

  • Research Site

    Nashville, Tennessee

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Florida, Argentina

  • Research Site

    La Rioja, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    San Miguel de Tucumán, Argentina

  • Research Site

    Viedma, Argentina

  • Research Site

    Fremantle, Australia

  • Research Site

    Southport, Australia

  • Research Site

    Waratah NSW, Australia

  • Research Site

    Westmead, Australia

  • Research Site

    Brussels, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Roeselare, Belgium

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Cachoeiro de Itapemirim, Brazil

  • Research Site

    Ijuí, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Vitória, Brazil

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Santiago, Chile

  • Research Site

    Baoding, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Bengbu, China

Showing 40 of 214 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.